Form 4: BioCryst Pharmaceuticals Director Steven Frank Acquires Shares and Options

Director Steven Frank acquired shares and options in BioCryst Pharmaceuticals through automatic non-employee director grants.

Summary

• On May 2, 2025, Steven Frank, a director of BioCryst Pharmaceuticals, acquired 1,866 shares of common stock and an option to purchase 4,079 shares of common stock.
• The acquisition of common stock was an automatic non-employee director grant of Restricted Stock Units (RSUs) pursuant to the company's Non-Employee Director Compensation Policy.
• These RSUs will vest in three equal annual installments starting on the one-year anniversary of the grant date.
• The option grant, also an automatic non-employee director grant, has an exercise price of $8.93.
• The options vest 1/36 per month over a 3-year period from the grant date and expire on May 2, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of shares and options by a director is generally viewed positively, but it's not a major event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.
• The vesting schedule of the RSUs and options incentivizes long-term commitment from the director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign of confidence in the company's future prospects.

Key Dates

Keywords

BioCryst Pharmaceuticals, Director, Steven Frank, Stock Options, Restricted Stock Units, BCRX, Form 4, Non-Employee Director Compensation Policy, Vesting